DB05230ExperimentalSmall molecule
AC3056 is a non-peptide antioxidant that acts as an inhibitor of vascular cell adhesion molecule expression originally developed by Aventis Pharmaceuticals. It as since been acquired by Amylin Pharmaceuticals and...
- Primary indication
- For the treatment of atherosclerosis and other conditions related to the obstruction of blood vessels.Curator reviewed
- Code names
- AC3056
Which companies are running trials of AC3056, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account